Differentiating systemic lupus erythematosus from other diseases: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 8: Line 8:
==Differentiating systemic lupus erythematosus from other diseases==
==Differentiating systemic lupus erythematosus from other diseases==
{| class="wikitable"
{| class="wikitable"
!
! colspan="2" |
!
!Overlapping Features
!
!Distinguishing/specific features
!
!
|-
|-
|Rheumatoid arthritis (RA)
| colspan="2" |Rheumatoid arthritis (RA)
|
|
|
|
|
|
|-
|-
|Rhupus
| colspan="2" |Rhupus
|
|
|
|
|
|
|-
|-
|Mixed connective tissue disease (MCTD)
| colspan="2" |Mixed connective tissue disease (MCTD)
|
|is characterized by overlapping features of SLE, systemic sclerosis (SSc), and polymyositis (PM), and by the presence of high titers of antibodies against U1 ribonucleoprotein (RNP)
|MCTD is a distinct clinical entity but it is evident that a subgroup of patients may evolve into another CTD during disease progression. Initial clinical features and autoantibodies can be useful to predict disease evolution
21959290
|
|
|-
| colspan="2" |Undifferentiated connective tissue disease (UCTD)
|arthritis and arthralgias, Raynaud phenomenon, and serological findings
signs and symptoms suggestive of a systemic autoimmune disease but do not satisfy the classification criteria for a defined connective tissue disease such as SLE or MCTD
|maintain an undefined profile and have a mild disease course
|
|
|-
|-
|Undifferentiated connective tissue disease (UCTD)
| colspan="2" |Systemic sclerosis (SSc)
|
|
|sclerodactyly, telangiectasias, calcinosis, and malignant hypertension with acute renal failure are more consistent with SSc
positive ANA is present in most patients with SSc, while other serologies such as anti-double-stranded DNA (dsDNA) and anti-Smith (Sm) antibodies
antibodies to an antigen called Scl-70 (topoisomerase I) or antibodies to centromere proteins
|
|
|-
| colspan="2" |Sjögren’s syndrome
|Extra-glandular manifestations
neurologic and pulmonary abnormalities
|keratoconjunctivitis sicca and xerostomia, and characteristic findings on salivary gland biopsy
commonly express antibodies to Ro and La antigens
|
|
|-
|-
|Systemic sclerosis (SSc)
| colspan="2" |Vasculitis
|medium and small vessel vasculitides such as polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA) (Wegener’s), or microscopic polyangiitis (MPA)
constitutional symptoms, skin lesions, neuropathy and renal dysfunction
|ANA-negative
|
|
|-
| colspan="2" |Behçet’s syndrome
|Oral aphthae
inflammatory eye disease, neurologic disease, vascular disease, and arthritis
|male dominancy and ANA-negative
vascular involvement of any size (small, medium, large) is more common
|
|
|-
| colspan="2" |Dermatomyositis (DM) and polymyositis (PM)
|positive ANA is observed in approximately 30 percent of patients
Gottron’s papules, a heliotrope eruption and photodistributed poikiloderma (including the shawl and V signs)
|more overt proximal muscle weakness than SLE
Absence of oral ulcers, arthritis, nephritis, and hematologic abnormalities
myositis-specific antibodies such as anti-Jo-1
|
|
|-
|-
|Sjögren’s syndrome
| colspan="2" |Adult Still’s disease (ASD)
|fever, arthritis or arthralgias, and lymphadenopathy
|leukocytosis
Negative ANA
|
|
|-
| colspan="2" |Kikuchi’s disease
|lymphadenopathy as well as fever, myalgias, arthralgias, and, less commonly, hepatosplenomegaly
|
|
* May be associated with SLE
* Spontaneous remission often occurring within four months
* lymph node biopsy, which reveals a histiocytic cellular infiltrate.
|
|
|-
|-
|Vasculitis
| colspan="2" |Serum sickness
|fever, lymphadenopathy, cutaneous eruptions, and arthralgias
during severe episodes, complement measurements including C3 and C4 can be depressed, as in SLE
|ANAs are typically negative and the course tends to be self-limited
|
|
|-
| colspan="2" |Fibromyalgia
|generalized arthralgias, myalgias, and fatigue
|SLE patients may have concomitant fibromyalgia as the prevalence of fibromyalgia in patients with systemic rheumatoid diseases is more.
|
|
|-
| rowspan="9" |Infections
| rowspan="7" |Viruses
|
* Human parvovirus B19:
** flu-like symptoms
** hematologic abnormalities such as leukopenia and thrombocytopenia
** arthralgias or arthritis.
|Serologic assays can be diagnostic for many of these viruses
|
|
|-
|-
|Behçet’s syndrome
|
|
* EBV
** May lead to a positive ANA
** 3020161     
|
|
|
|
|-
|-
|Dermatomyositis (DM) and polymyositis (PM)
|Human immunodeficiency virus (HIV)
|
|
|
|-
|Hepatitis B virus (HBV)
|
|
|
|
|-
|-
|Adult Still’s disease (ASD)
|Hepatitis C virus (HCV)
|
|
|
|-
|Cytomegalovirus (CMV)
|
|
|
|
|-
|-
|Kikuchi’s disease
|Epstein-Barr virus (EBV)
|
|
|
|-
| rowspan="2" |Bacterias
|Salmonella
|
|
|
|
|-
|-
|Serum sickness
|tuberculosis
|
|
|
|
|-
| colspan="2" |Multiple sclerosis (MS)
|cranial neuropathies
|Unilateral optic neuritis and pyramidal syndrome, with lesions detected by magnetic resonance imaging (MRI) suggesting dissemination in space and time are characteristic of MS
|
|
|-
|-
|Fibromyalgia
| colspan="2" |Malignancies
|
|
* Leukemia or myelodysplastic syndromes
* hematologic and constitutional symptoms similar to those observed in SLE
* lymphoma
|
|
* Monoclonal expansion of B and T cells (as assessed by immunophenotyping), monocytosis, or macrocytosis can distinguish these malignancies from SLE
* Splenomegaly, lymphadenopathy, or increased lactate dehydrogenase (LDH) levels that are not observed in SLE but in lymphoma
* Excisional tissue biopsy specially from lymph nodes in the case of lymphomas
|
|
|-
|-
|Infections
| colspan="2" |Thrombotic thrombocytopenic purpura (TTP)
|fever and thrombocytopenia
|
|
* Human parvovirus B19:
* Microangiopathic hemolytic anemia
** flu-like symptoms
* Acute renal insufficiency
** hematologic abnormalities such as leukopenia and thrombocytopenia
* Fluctuating neurological manifestations
** arthralgias or arthritis.
* Low levels of ADAMSTS13
|
|
|-
|
|
|-
|
|
|
|
* EBV
** May lead to a positive ANA
** 3020161     
|
|
|
|
|-
|-
|
|
|Human immunodeficiency virus (HIV)
|
|
|
|
|
|
|-
|-
|
|
|Hepatitis B virus (HBV)
|
|
|
|
|
|
|-
|-
|
|
|Hepatitis C virus (HCV)
|
|
|
|
|
|
|-
|-
|
|Cytomegalovirus (CMV)
|
|
|
|
|-
|
|
|Epstein-Barr virus (EBV)
|
|
|
|

Revision as of 21:43, 17 June 2017


Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Differentiating systemic lupus erythematosus from other diseases On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Differentiating systemic lupus erythematosus from other diseases

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Differentiating systemic lupus erythematosus from other diseases

on Differentiating systemic lupus erythematosus from other diseases

Differentiating systemic lupus erythematosus from other diseases in the news

Blogs onDifferentiating systemic lupus erythematosus from other diseases

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Differentiating systemic lupus erythematosus from other diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Differentiating systemic lupus erythematosus from other diseases

Overlapping Features Distinguishing/specific features
Rheumatoid arthritis (RA)
Rhupus
Mixed connective tissue disease (MCTD) is characterized by overlapping features of SLE, systemic sclerosis (SSc), and polymyositis (PM), and by the presence of high titers of antibodies against U1 ribonucleoprotein (RNP) MCTD is a distinct clinical entity but it is evident that a subgroup of patients may evolve into another CTD during disease progression. Initial clinical features and autoantibodies can be useful to predict disease evolution

21959290

Undifferentiated connective tissue disease (UCTD) arthritis and arthralgias, Raynaud phenomenon, and serological findings

signs and symptoms suggestive of a systemic autoimmune disease but do not satisfy the classification criteria for a defined connective tissue disease such as SLE or MCTD

maintain an undefined profile and have a mild disease course
Systemic sclerosis (SSc) sclerodactyly, telangiectasias, calcinosis, and malignant hypertension with acute renal failure are more consistent with SSc

positive ANA is present in most patients with SSc, while other serologies such as anti-double-stranded DNA (dsDNA) and anti-Smith (Sm) antibodies

antibodies to an antigen called Scl-70 (topoisomerase I) or antibodies to centromere proteins

Sjögren’s syndrome Extra-glandular manifestations

neurologic and pulmonary abnormalities

keratoconjunctivitis sicca and xerostomia, and characteristic findings on salivary gland biopsy

commonly express antibodies to Ro and La antigens

Vasculitis medium and small vessel vasculitides such as polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA) (Wegener’s), or microscopic polyangiitis (MPA)

constitutional symptoms, skin lesions, neuropathy and renal dysfunction

ANA-negative
Behçet’s syndrome Oral aphthae

inflammatory eye disease, neurologic disease, vascular disease, and arthritis

male dominancy and ANA-negative

vascular involvement of any size (small, medium, large) is more common

Dermatomyositis (DM) and polymyositis (PM) positive ANA is observed in approximately 30 percent of patients

Gottron’s papules, a heliotrope eruption and photodistributed poikiloderma (including the shawl and V signs)

more overt proximal muscle weakness than SLE

Absence of oral ulcers, arthritis, nephritis, and hematologic abnormalities

myositis-specific antibodies such as anti-Jo-1

Adult Still’s disease (ASD) fever, arthritis or arthralgias, and lymphadenopathy leukocytosis

Negative ANA

Kikuchi’s disease lymphadenopathy as well as fever, myalgias, arthralgias, and, less commonly, hepatosplenomegaly
  • May be associated with SLE
  • Spontaneous remission often occurring within four months
  • lymph node biopsy, which reveals a histiocytic cellular infiltrate.
Serum sickness fever, lymphadenopathy, cutaneous eruptions, and arthralgias

during severe episodes, complement measurements including C3 and C4 can be depressed, as in SLE

ANAs are typically negative and the course tends to be self-limited
Fibromyalgia generalized arthralgias, myalgias, and fatigue SLE patients may have concomitant fibromyalgia as the prevalence of fibromyalgia in patients with systemic rheumatoid diseases is more.
Infections Viruses
  • Human parvovirus B19:
    • flu-like symptoms
    • hematologic abnormalities such as leukopenia and thrombocytopenia
    • arthralgias or arthritis.
Serologic assays can be diagnostic for many of these viruses
  • EBV
    • May lead to a positive ANA
    • 3020161
Human immunodeficiency virus (HIV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Cytomegalovirus (CMV)
Epstein-Barr virus (EBV)
Bacterias Salmonella
tuberculosis
Multiple sclerosis (MS) cranial neuropathies Unilateral optic neuritis and pyramidal syndrome, with lesions detected by magnetic resonance imaging (MRI) suggesting dissemination in space and time are characteristic of MS
Malignancies
  • Leukemia or myelodysplastic syndromes
  • hematologic and constitutional symptoms similar to those observed in SLE
  • lymphoma
  • Monoclonal expansion of B and T cells (as assessed by immunophenotyping), monocytosis, or macrocytosis can distinguish these malignancies from SLE
  • Splenomegaly, lymphadenopathy, or increased lactate dehydrogenase (LDH) levels that are not observed in SLE but in lymphoma
  • Excisional tissue biopsy specially from lymph nodes in the case of lymphomas
Thrombotic thrombocytopenic purpura (TTP) fever and thrombocytopenia
  • Microangiopathic hemolytic anemia
  • Acute renal insufficiency
  • Fluctuating neurological manifestations
  • Low levels of ADAMSTS13

References